Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.79 and traded as low as $2.79. Galmed Pharmaceuticals shares last traded at $2.93, with a volume of 19,606 shares.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They issued a “sell” rating for the company.
View Our Latest Stock Analysis on Galmed Pharmaceuticals
Galmed Pharmaceuticals Trading Down 1.0 %
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- 3 Ways To Invest In Coffee, Other Than Drinking It
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Using the MarketBeat Dividend Yield Calculator
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
